UCLA David Geffen School of Medicine
Welcome,         Profile    Billing    Logout  
 27 Trials 
31 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Saver, Jeffrey
EMAGINE, NCT05044507: The Efficacy of a Frequency-tuned Electromagnetic Field Treatment in Facilitating the Recovery of Subacute Ischemic Stroke Patients - a Pivotal Study (THE "" STUDY)

Completed
N/A
100
US
BQ 2.0, BQ 2.0 sham stimulation group, BQ 2.0 active stimulation group
BrainQ Technologies Ltd.
Ischemic Stroke
11/23
01/24
NCT06386874: EMAGINE 2.0 - Electromagnetic Field Ischemic Stroke - Novel Subacute Treatment

Recruiting
N/A
122
US
Q Therapeutic System (BQ 3.0) - Sham, BQ 3.0 Sham Stimulation Group, Q Therapeutic System (BQ 3.0) - Active, BQ 3.0 Active Stimulation Group Interventions
BrainQ Technologies Ltd.
Ischemic Stroke
07/26
10/26
Cooper, Christopher J
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1633
Europe, Japan, US, RoW
Lasmiditan, LY573144, Placebo
Eli Lilly and Company
Migraine
01/25
01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine

Recruiting
3
1000
Europe, Japan, US, RoW
Lasmiditan, LY573144
Eli Lilly and Company
Migraine
03/26
03/26
Rettig, Matthew B
PSMAddition, NCT04720157 / 2020-003968-56: An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

Jan 2024 - Dec 2024: Primary data from PSMAddition trial for metastatic hormone sensitive prostate cancer
Active, not recruiting
3
1145
Europe, Canada, Japan, US, RoW
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Novartis Pharmaceuticals, Alliance Foundation Trials, LLC., RTOG Foundation, Inc.
Prostatic Neoplasms
07/25
02/26
NCT02881242: Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

Active, not recruiting
2
14
US
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
Jonsson Comprehensive Cancer Center, Stand Up To Cancer, Novartis, Prostate Cancer Foundation
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer
01/24
01/25
CHOMP, NCT04104893: A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Recruiting
2
30
US
Pembrolizumab, Keytruda
VA Office of Research and Development, Merck Sharp & Dohme LLC
Metastatic Castration Resistant Prostate Cancer
03/25
12/25
BRCAAway, NCT03012321: Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

Active, not recruiting
2
70
US
Olaparib, Lynparza, Abiraterone Acetate, Prednisone
Northwestern University, AstraZeneca, National Cancer Institute (NCI)
Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
12/26
01/27
CaRe, NCT06056791: Study of INKmune in Patients With mCRPC ( Prostate)

Recruiting
1/2
30
US
INKmune
Inmune Bio, Inc.
Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
05/25
11/25
NCT03386071: Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

No Longer Available
N/A
NA
Trametinib 2 mg
Jonsson Comprehensive Cancer Center, Novartis
Progressive Metastatic Castrate Resistant Prostate Cancer
 
 
Tashkin, Donald P
RARICO, NCT04315558: Revefenacin in Acute Respiratory Insufficiency in COPD

Recruiting
2
21
US
Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide
University of California, Los Angeles, Theravance Biopharma, Mylan Pharmaceuticals Inc
COPD, Acute Respiratory Failure
04/25
06/25
Liebeskind, David S
CAPTIVA, NCT05047172: Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis

Recruiting
3
1683
US
Ticagrelor + Aspirin, Brilinta, Rivaroxaban + Aspirin, Xarelto, Clopidogrel + Aspirin, Plavix, Risk Factor Management
University of Florida, National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati, Medical University of South Carolina, Janssen Scientific Affairs, LLC, AstraZeneca
Intracranial Arteriosclerosis, Stroke
05/28
05/28
McMahon, Maureen
SELUNE, NCT04181762 / 2019-003211-57: Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis

Terminated
3
275
Europe, Canada, Japan, US, RoW
secukinumab, AIN457, Placebo
Novartis Pharmaceuticals
Lupus Nephritis
09/23
09/23
SIRIUS-LN, NCT05126277 / 2020-005830-14: Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

Recruiting
3
420
Europe, Canada, US, RoW
ianalumab s.c. q4w, VAY736, ianalumab s.c. q12w, placebo s.c., placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Lupus Nephritis
03/27
07/30
NCT05000216: COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Completed
2
257
US
Moderna mRNA-1273, mRNA-1273 vaccine (Moderna), Moderna COVID-19 Vaccine, SARS-CoV-2 RNA vaccine, COVID-19 vaccine, BNT162b2, mRNA-1273 vaccine (Pfizer/BioNTech), Pfizer-BioNTech COVID-19 vaccine, Ad26.COV2.S, Janssen COVID-19 Vaccine, JNJ-78436735, Continue IS (MMF or MPA), immunosuppressive medication, mycophenolate mofetil, MMF, CellCept®, mycophenolic acid, MPA, Continue IS (MTX), methotrexate, MTX, Continue IS (B cell depletion therapy), mAbs targeting CD19 or CD20, anti-BAFF mAb, Monovalent [B.1.351] CoV2 preS dTM-AS03, Sanofi-GSK COVID-19 Vaccine, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, mRNA-1273 vaccine (Moderna), Bivalent, Moderna COVID-19 Vaccine, Bivalent, SARS-CoV-2 RNA vaccine, Bivalent, COVID-19 vaccine, Bivalent, BNT162b2, Bivalent, mRNA-1273 vaccine (Pfizer/BioNTech), Bivalent, Pfizer-BioNTech COVID-19 vaccine, Bivalent
National Institute of Allergy and Infectious Diseases (NIAID), Autoimmunity Centers of Excellence, Rho Federal Systems Division, Inc.
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
06/23
03/24
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

Recruiting
1/2
30
US, RoW
IMPT-514
ImmPACT Bio
Systemic Lupus Erythematosus, Lupus Nephritis
02/27
02/27
Coordinator
NCT05070455: An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

Recruiting
4
12
US
Asceniv™
ADMA Biologics, Inc.
Primary Immune Deficiency
03/23
06/23
VRDN-001-302, NCT06179875: An Open-label Study for Participants Who Are Non-responders at the End of Treatment Assessment on the VRDN-001-101 and VRDN-001-301 Pivotal Studies

Recruiting
3
143
Europe, US
Intervention/Treatment
Viridian Therapeutics, Inc.
Thyroid Eye Disease
07/25
03/26
RECOVER, NCT05184335: Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

Recruiting
3
690
US
Brilaroxazine, RP5063, Placebo
Reviva Pharmaceuticals
Schizophrenia
02/25
02/25
STRIVE, NCT06384547: A Randomized, Active Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)

Recruiting
3
212
US
VRDN-001 10 mg/kg, VRDN-001 3 mg/kg
Viridian Therapeutics, Inc.
Thyroid Eye Disease
05/25
01/26
REVEAL-1, NCT06625411: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED)

Recruiting
3
84
US
VRDN-003, Placebo
Viridian Therapeutics, Inc.
Thyroid Eye Disease
03/26
11/26
REVEAL-2, NCT06625398: An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED)

Recruiting
3
126
US
VRDN-003, Placebo
Viridian Therapeutics, Inc.
Thyroid Eye Disease
04/26
12/26
THRIVE-2, NCT06021054: An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants with Chronic Thyroid Eye Disease (TED)

Active, not recruiting
3
188
Europe, US, RoW
Veligrotug (VRDN-001), Placebo
Viridian Therapeutics, Inc.
Thyroid Eye Disease
12/24
09/25
NCT04222062: A Study Comparing GLIADEL to Stereotactic Radiosurgery in Metastatic Brain Disease

Recruiting
2
100
US
Carmustine 7.7Mg Wafer, GLIADEL
University of Nebraska, Arbor Pharmaceuticals, Inc.
Brain Tumor - Metastatic
12/25
12/26
NCT06107686: A Study of YL202 in Selected Patients with Advanced Solid Tumors

Recruiting
2
200
RoW
YL202 should be intravenously infused
MediLink Therapeutics (Suzhou) Co., Ltd.
NSCLC, Breast Cancer, HNSCC, Locally Advanced or Metastatic Solid Tumors
11/26
11/28
NCT06057922: A Study YL201 in Patients With Selected Advanced Solid Tumors

Recruiting
1/2
640
RoW
YL201 for Injection
MediLink Therapeutics (Suzhou) Co., Ltd.
Advanced Solid Tumor
10/26
10/27
NCT06186596: Self-Administered Intralesional Injections for Acne

Recruiting
N/A
150
US
Triamcinolone delivered via injection assistance device
ACOM Labs
Acne Vulgaris
01/24
01/24
PRIMA-102, NCT05936970: Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to a DMARD Starting a New BDMARD or TsDMARD Treatment +/- CsDMARD

Recruiting
N/A
1410
US
Aqtual, Inc.
Rheumatoid Arthritis
06/25
12/25
NCT05100836: SURPASS Impella 5.5 Study

Active, not recruiting
N/A
1017
US
Impella 5.5
Abiomed Inc.
Cardiogenic Shock, Acute Decompensated Heart Failure
03/25
03/25
Wang, Tisha
IMPALA-2, NCT04544293 / 2020-001263-85: Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Active, not recruiting
3
160
Europe, Canada, Japan, US, RoW
Molgramostim, Recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF), Placebo
Savara Inc., Savara ApS,
Autoimmune Pulmonary Alveolar Proteinosis
11/23
11/24
Bevis, Danielle
PACIFICA, NCT03165734 / 2017-001772-28: A Phase 3 Study of Pacritinib in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis

Calendar May 2026 - Sep 2026: Data from PACIFICA trial for myelofibrosis
Recruiting
3
399
Europe, Canada, US, RoW
Pacritinib, Physician's Choice medications, corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib
Swedish Orphan Biovitrum, PSI CRO
Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
12/26
07/27
Wilson, Rujuta B
No trials found

Download Options